OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Blad... (f cancers. About OncoGenex .....)

OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer

Date:8/13/2009

f cancers.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

OGX-011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS), to effectively target and inhibit production of specific proteins in tumor cells. OncoGenex and Isis partnered in the successful discovery of OGX-011, OGX-427 and OGX-225 and with respect to OGX-011, in its initial development. In 2008, OncoGenex and Isis amended their OGX-011 agreement to provide OncoGenex with sole rights to OGX-011 and sole responsibility for development and related costs and partnering decisions, subject to financial obligations to Isis. OncoGenex is also solely responsible for development and related costs and partnering decisions regarding OGX-427 and OGX-225. Key intellectual property related to OGX-011, OGX-427 and OGX-225 were discovered by the University of British Columbia and the Vancouver Prostate Centre, and were exclusively licensed to OncoGenex.

More information about OncoGenex is available at www.oncogenex.com.

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
2. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
3. Cellectar Expands Clinical Management Team
4. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
5. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
6. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
7. PAREXEL Expands Global Clinical Pharmacology Capabilities
8. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
9. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
10. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
11. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center

Post Your Comments:

(Date:12/15/2009)... Varian Medical Systems (NYSE: VAR ) announced ... of fiscal year 2010 following the close of regular ... release will be followed by a teleconference available to ... news release and a link to the conference call ... www.varian.com/investor . To access the teleconference call ...

(Date:12/15/2009)... Masimo (Nasdaq: MASI ), the ... Low Perfusion pulse oximetry, today announced that Masimo ... the 2009 Frost & Sullivan CEO of the ... market. According to Frost & Sullivan, the award ... ability in understanding customer requirements, developing new technologies, ...

(Date:12/15/2009)... HAVEN, Conn., Dec. 15 Rib-X Pharmaceuticals, ... and commercialization of novel drugs for the treatment ... entered into a collaborative research agreement with Massachusetts ... science plan for the collaboration, Dr. David Hooper ... in an established animal model to determine resistance ...

[0] Varian Medical Systems Schedules First Quarter FY2010 News Release and Conference Call [0] Masimo Chairman and CEO Joe Kiani Receives 2009 Frost & Sullivan CEO of the Year Award [0] Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital

... 2007 /PRNewswire-FirstCall/ - Research,collaborators with Oncolytics Biotech ... presentation covering REOLYSIN(R),clinical trial data at the ... to be held June 1-5, 2007 in ... U.K. Phase I systemic,administration trial. , The ...

... 2007 - A therapeutic,vaccine developed by the ... new hope for cancer patients. The results ... presented to an,international audience at the Annual ... (ASCO) in Chicago, USA. ASCO is the,most ...

Other Medicine Technology:Oncolytics Biotech Inc.'s Research Collaborators to Present,REOLYSIN Clinical Trial Data at ASCO Conference 2 Vakzine Projekt Management Reports Positive Clinical Trial Results,With Their Therapeutic Prostate Cancer Vaccine VPM4001 2

Oncolytics Biotech Inc.'s Research Collaborators to Present,REOLYSIN Clinical Trial Data at ASCO Conference Vakzine Projekt Management Reports Positive Clinical Trial Results,With Their Therapeutic Prostate Cancer Vaccine VPM4001

(Date:12/14/2009)... new liposuction and fat transfer treatments can help people slim ... minimally invasive treatment. , ... (PRWEB) ... can remove excess fat from the abdomen and inject it ... reduce facial wrinkling and enhance lips all in one safe, ...

(Date:12/14/2009)... Dec. 14 Americold Realty Trust ("Americold") announced ... Form S-11 with the U.S. Securities and Exchange Commission ... of its common shares. The number of shares to ... have not yet been determined. The common shares to ... sold by Americold. ,, The joint book-running managers ...

(Date:12/14/2009)... Aflac Incorporated announced today that it has priced ... with a coupon of 6.9%. The notes will ... yield 6.984%. The company anticipates using the proceeds ... corporate purposes. ,, Commenting on the pricing of ... Financial Officer Kriss Cloninger III commented: "This debt ...

(Date:12/14/2009)... NAPA, Calif., Dec. 14 Tough Enough To ... fight breast cancer, celebrated its fifth anniversary at ... at the Wrangler National Finals Rodeo (Wrangler NFR) ... associated with rough-and-tumble rodeo cowboys, the support of ... as the sold-out crowd sported pink shirts, hats, ...

(Date:12/14/2009)... Canada for 13 years under government controlled health care, before moving ... In speaking engagements and in his new book, Health Reform: The ... of such a system and its threat to real health care! ... ... Kurisko , a diagnostic radiologist from Minnesota, warns Americans not to ...

Breaking Medicine News(10 mins):Health News: Free Webinar Series at Aqualipo.com Shows How New Combination Liposuction/Fat Transfer Treatment Helps Patients Slim Down and Reduce Facial Wrinkling 2 Health News: Free Webinar Series at Aqualipo.com Shows How New Combination Liposuction/Fat Transfer Treatment Helps Patients Slim Down and Reduce Facial Wrinkling 3 Health News:Americold Realty Trust Files Registration Statement for Proposed Initial Public Offering 2 Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 2 Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 3 Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 4 Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 2 Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 3 Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 4 Health News:Canadian Doctor Warns Against Government-Run, Socialized Medicine and its Threat to Health Care and Freedom in America 2

[0] Free Webinar Series at Aqualipo.com Shows How New Combination Liposuction/Fat Transfer Treatment Helps Patients Slim Down and Reduce Facial Wrinkling [0] Americold Realty Trust Files Registration Statement for Proposed Initial Public Offering [0] Aflac Incorporated Prices $400 Million of 30-Year Senior Notes [0] Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary [2] Canadian Doctor Warns Against Government-Run, Socialized Medicine and its Threat to Health Care and Freedom in America

... 4 SAFC Pharma(TM), a focus,area within SAFC(R) ... (Nasdaq: SIAL ), today officially announced details,of ... (Wisconsin) facility,designed to significantly increase its capacity to ... The investment,includes the purchase of 15 acres of ...

... Entire Region Won,t Succumb to the Pressure, ORLANDO, Fla., ... High Blood Pressure in our lifetime, but that data doesn,t ... to fight the,silent killer. Today, Orlando Mayor Buddy Dyer was ... first of its kind health,initiative to promote healthier outcomes for ...

... Secretary Mike,Leavitt today welcomed 11 more community collaborations ... care system where consumers, providers,and payers make decisions ... These communities will join 14 others as ... care providers, employers,insurers, and consumers working jointly to ...

... levels triple risk of aggressive disease , , WEDNESDAY, Sept. ... fall within the high end of the normal range ... cancer, a new report shows. , The results suggest ... cancer, the researchers said. But one expert cautioned against ...

... that individual cells in the immune system use to ... signals the researchers detected originated in dendritic cells ... initial detection of microscopic invaders and were received ... roles in the immune system, including coordination of attacks ...

... grants will be awarded to Texas ... public interest attorneys, AUSTIN, Texas, Sept. 3 ... allotment of grants,totaling more than $24 million, will be distributed to 40 ... TAJF was created by the Supreme Court of Texas and is the ...

Other Medicine News:Health News:SAFC Pharma(TM) Commits to Major Expansion of High Potency API Production at Madison Site 2 Health News:SAFC Pharma(TM) Commits to Major Expansion of High Potency API Production at Madison Site 3 Health News:Mayor Issues Million Resident Challenge To Educate Central Florida About Blood Pressure 2 Health News:Mayor Issues Million Resident Challenge To Educate Central Florida About Blood Pressure 3 Health News:Mayor Issues Million Resident Challenge To Educate Central Florida About Blood Pressure 4 Health News:Mayor Issues Million Resident Challenge To Educate Central Florida About Blood Pressure 5 Health News:Mayor Issues Million Resident Challenge To Educate Central Florida About Blood Pressure 6 Health News:HHS Designates 11 Communities Working to Improve Quality and Value of Health Care As Chartered Value Exchanges 2 Health News:HHS Designates 11 Communities Working to Improve Quality and Value of Health Care As Chartered Value Exchanges 3 Health News:Study Links Serum Calcium, Prostate Cancer Death 2 Health News:Study Links Serum Calcium, Prostate Cancer Death 3 Health News:New nano device detects immune system cell signaling 2 Health News:New nano device detects immune system cell signaling 3 Health News:New nano device detects immune system cell signaling 4 Health News:New nano device detects immune system cell signaling 5 Health News:Texas Access to Justice Foundation Awards More Than $24 Million to Nonprofits Across the State for Legal Aid to Poor 2 Health News:Texas Access to Justice Foundation Awards More Than $24 Million to Nonprofits Across the State for Legal Aid to Poor 3 Health News:Texas Access to Justice Foundation Awards More Than $24 Million to Nonprofits Across the State for Legal Aid to Poor 4

SAFC Pharma(TM) Commits to Major Expansion of High Potency API Production at Madison Site Mayor Issues Million Resident Challenge To Educate Central Florida About Blood Pressure HHS Designates 11 Communities Working to Improve Quality and Value of Health Care As Chartered Value Exchanges Study Links Serum Calcium, Prostate Cancer Death New nano device detects immune system cell signaling Texas Access to Justice Foundation Awards More Than $24 Million to Nonprofits Across the State for Legal Aid to Poor

Inorganic phosphorus (UV method) reagent is for the quantitative determination of inorganic phosphorus in human serum....

Inorganic phosphorus reagent is used for the quantitative determination of inorganic phosphorus in human serum....

For the quantitative determination of Inorganic Phosphorus in serum. Linearity: 12.0 mg/dl....

Amylase (EPS-G7, kinetics), Wavelength: 405 nm. Linear range; 5-1500 IU/L....

Medicine Products:

Inorganic Phosphorus UV Reagent Set Inorganic Phosphorus Color Reagent Inorganic Phosphorus (Liquid)Amylase (EPS-G7, kinetics)

OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Blad...(f cancers. About OncoGenex .....),Health